New ultrasound software could simplify fatty liver diagnosis
NCT ID NCT07268937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether special software on standard ultrasound machines can accurately measure liver fat in people with non-alcoholic fatty liver disease (NAFLD). Researchers compared the ultrasound results to the Fibroscan CAP method in 25 adults. The goal was to see if the ultrasound software could be a simpler, non-invasive tool for diagnosing fatty liver.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simpler, cheaper way to diagnose fatty liver disease using standard ultrasound machines.
- What could go wrong
- This is a small, completed comparison study with only 25 participants. The software may not be as accurate as the Fibroscan, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
25 people
The number who actually took part.
- Started
-
Jul 2023
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with an age \> 18 years
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * age \> 18 years, * ability to hold breath for image acquisition, * informed consent Exclusion Criteria: * withdrawal of informed consent, * any condition which, in the clinical judgement of the investigator, will make further participation in the study unacceptable for that individual patient
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease (NAFLD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo, SSD Malattie Infettive 3 - Ecografia
Pavia, Pavia, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 10-Year quest to uncover fatty Liver's hidden toll in china
- Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers
- New ultrasound device could replace costly MRI for liver disease detection
- Bee product could tame fatty liver and blood fats
- Diabetes drugs may reverse fatty liver damage in new trial
- Can Omega-3 and diet advice tame fatty liver disease?